Skip to content skip to primary navi skip to secondary navi skip to meta navi search

Publications 2005

Original Papers

  • Ballova V*, Rüffer JU*, Haverkamp H, Pfistner B, Müller-Hermelink HK, Dühmke E, Worst P, Wilhelmy M, Naumann R, Hentrich M, Eich HT, Josting A, Löffler M, Diehl V, Engert A. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9 elderly). Ann Oncol 2005; 16 (1):124-131. [*Both authors contributed equally to this work.]
  • Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, Schmitz T, Wildt L, Diehl V, Engert A; German Hodgkin's Lymphoma Study Group. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2005; 23(30):7555-64. 
  • Darabi K, Sieber M, Chaitowitz M, Braitman LE, Tester W, Diehl V.Infradiaphragmatic versus supradiaphragmatic Hodgkin lymphoma: a retrospective review of 1,114 patients. Leuk Lymphoma 2005; 46(12):1715-20.
  • Eich HT, Haverkamp U, Engert A, Kocher M, Skripnitchenko R, Brillant C, Sehlen S, Dühmke E, Diehl V, Müller R-P. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin’s Lymphoma – a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys 2005; 63 (3): 860-865.
  • Engert A, Ballova V, Haverkamp H, Pfistner B, Josting A, Dühmke E, Müller-Hermelink K, Diehl V; German Hodgkin's Study Group. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol. 2005; 23(22):5052-60.
  • Glossmann JP, Staak JO, Nogova L, Diehl V, Scheid C, Kisro J, Reis HE, Peter N, Engert A, Josting A. Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma. Ann Hematol. 2005; 84(8):517-25.
  • Josting A, Nogova L, Franklin J, Glossmann JP, Eich HT, Sieber M, Schober T, Boettcher HD, Schulz U, Mueller R-P, Diehl V, Engert A. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's Lymphoma: A retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 2005; 23 (7): 1522-1529.
  • Josting A, Rudolph C, Mapara M, Glossmann JP, Sieniawski M, Sieber M, Kirchner HH, Dörken B, Hossfeld DK, Kisro J, Metzner B, Berdel WE, Diehl V, Engert A. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol. 2005; 16(1):116-23.
  • Klimm B, Reineke T, Haverkamp H, Behringer K, Eich HT, Josting A, Pfistner B, Diehl V, Engert A. Role of hematotoxicity in female patients with Hodgkin’s lymphoma. J Clin Oncol 2005; 23(31): 8003-11.
  • Nogova L, Reineke T, Eich HT, Josting A, Müller-Hermelink HK, Wingbermühle K, Brillant C, Gossmann A, Oertel J, Bollen MV, Müller R-P, Diehl V, Engert A. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 2005; 16 (10): 1683-1687.
  • Rüffer JU, Ballova V, Glossmann J, Sieber M, Franklin J, Nogova L, Diehl V, Josting A; German Hodgkin Study Group. BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group. Leuk Lymphoma. 2005 Nov;46(11):1561-7.
  • Schnell R*, Dietlein M*, Staak JO, Borchmann P, Schomäcker K, Fischer T, Eschner W, Hansen H, Morschhauser F, Schicha H, Diehl V, Raubitschek A, Engert A. Treatment of refractory Hodgkin lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody (131I-Ki-4). J Clin Oncol 2005; 23: 4669-4678. [*Both authors contributed equally to this work.]
  • Shimabukuro-Vornhagen A, Haverkamp H, Engert A, Balleisen L, Majunke P, Heil G, Eich HT, Stein H, Diehl V, Josting A. Lymphocyte-rich classical Hodgkin lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin’s Study Group trials. J Clin Oncol 2005; 23 (24):5739-5745. 
  • Smardova L, Engert A, Haverkamp H, Raemakers J, Baars J, Pfistner B, Diehl V, Josting A. Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease. Leuk Lymphoma. 2005; 46(7):1017-22.
  • Weihrauch MR, Manzke O, Beyer M, Haverkamp H, Diehl V, Bohlen H, Wolf J, Schultze JL. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Res. 2005 Jul 1;65(13):5516-9.

Reviews